RIR and the Impact on Clinical Outcomes in Patients Undergoing PCI

Serial hsCRP measurements with ≥ 4 weeks between both measurements are defined in this analysis. Time-to-event is measured from first hsCRP measurement.

Inclusion criteria

• Participants who understand and sign the informed consent form voluntarily;
• Age ≥ 18 years old and ≤ 80 years old, regardless of sex;
• The hospitalized patients with coronary heart disease undergoing PCI;
• Complete all planned PCI during hospitalization

Exclusion criteria

• Patients do not receive standardized treatment according to guidelines after being diagnosed with coronary heart disease;
• Uncontrolled infectious diseases during the screening period;
• In the screening stage, patients with immune diseases or immune-related diseases such as systemic lupus erythematosus, asthma, inflammatory bowel disease, gout, malignant tumor and so on;
• Long-term use of non-steroidal anti-inflammatory drugs, hormones, immunomodulatory and chemotherapeutic drugs during the study period;
• Surgical or interventional treatment was performed within 3 months before the screening period;
• Pregnant women, lactating women or women of childbearing age who do not use effective contraceptives;
• Participated in other clinical trials within 3 months before the screening period;
• The researchers determined that other conditions in which the patient was not suitable to participate in the clinical trial.